1-5 of 5
Emil T. Kuriakose
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro
Journal: Blood
Blood (2024) 144 (Supplement 1): 6594.
https://doi.org/10.1182/blood-2024-204153
Published: 2024
Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 12125–12126.
https://doi.org/10.1182/blood-2022-165502
Published: 2022
Journal Articles

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma

Vincent L Hansen, MD, Morton Coleman, MD, Stephanie Elkins, MD, Jeffrey P. Letzer, Moshe Yair Levy, MD, Lasika Seneviratne, MD, Jessica Rine, Marina White, Emil T Kuriakose, MD
Journal: Blood
Blood (2015) 126 (23): 3027.
https://doi.org/10.1182/blood.V126.23.3027.3027
Published: 2015
Journal Articles

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Hongbo Yang, PhD, Anuja Roy, PhD, Chelsey Yang, Evangeline McDonald, Arun Krishna, PhD, Emil T Kuriakose, MD, Denise Globe, PhD, David Siegel, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2015) 126 (23): 5369.
https://doi.org/10.1182/blood.V126.23.5369.5369
Published: 2015
Journal Articles

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Sundar Jagannath, MD, Anuja Roy, PhD, Jonathan K Kish, PhDMPH, Denise Globe, PhD, Orsolya Lunacsek, PhDMBA, Michael T. Eaddy, PharmD, PhD, Emil T Kuriakose, MD, Joanne Willey, RN, David Siegel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3311.
https://doi.org/10.1182/blood.V126.23.3311.3311
Published: 2015